Business Wire

AIT Worldwide Logistics acquires European life sciences specialist Mach II Shipping Ltd

Share

AIT Worldwide Logistics, a global supply chain solutions leader, has acquired Mach II Shipping Ltd, a U.K.-based freight forwarder specializing in worldwide distribution of pharmaceuticals and related products. The deal includes a subsidiary in the Netherlands in addition to a global network of life sciences partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231204606803/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ultra-low temperature freezer farm units at Mach 2 Pharmafreight's Netherlands facility. (Photo: Business Wire)

According to AIT’s Executive Vice President, Life Sciences, Chris Amberg, the acquired company (commonly known as Mach 2 or Pharmafreight) has earned a reputation for extremely high-quality shipping solutions in the demanding life sciences industry, including transportation programs for clinical trials, active pharmaceutical ingredients (APIs), pharmaceutical machinery, and finished products.

“In addition to temperature-controlled air freight, Mach 2 provides outstanding dedicated road service for high-value life sciences moves throughout Europe with a managed fleet of temperature-controlled vehicles operated by Good Distribution Practices-trained independent contractors,” Amberg said. “Additionally, their value-added services include in-house customs clearance and a temperature-controlled warehouse in Ashford, Middlesex, near London Heathrow Airport.”

Services at the Ashford location are mirrored by a second office in the Netherlands, opened in 2019 as a response to the United Kingdom’s withdrawal from the European Union. Customers requiring a post-Brexit alternative to working in the U.K. receive the same top-quality standard of service from the Nieuw-Vennep office, located just minutes away from Amsterdam Airport Schiphol, while avoiding Brexit-related customs or regulatory challenges. The Netherlands facility features an ultra-low temperature (ULT) freezer farm, safely and securely storing oncology products at below -60°C.

Mach 2’s global Pharmafreight partner network is also included as part of the acquisition. Formed in 2000, the network has grown over the past two decades under the leadership of Mach 2 Shipping Commercial Director, Andy Hughes. As a result of careful recruitment and vetting, Pharmafreight is a first-rate collective of audited, approved independent freight forwarders operating under Good Distribution Practices in 30 countries across Africa, Asia, Europe, North America, and South America.

In addition to promoting best practices for total quality across the network, Pharmafreight ensures consistent quality with international partner training (including GDP training) and a global sales call program to boost cooperation between network partners.

“Our teammates across Mach 2 and Pharmafreight are eagerly continuing to provide stable, high-quality service for our customers as we prepare to integrate fully with AIT in 2024,” Hughes said. “This acquisition is providing a phenomenal opportunity to enhance our solutions for customers as we tap into AIT’s vast worldwide network.”

“I’m delighted to welcome Mach 2 and Pharmafreight teammates to the company,” said AIT’s President and Chief Operating Officer, Keith Tholan. “Their well-tenured expertise provides an instant boost to our world-class Life Sciences Division, and we look forward to elevating cold chain service for our customers, especially in Europe.”

In addition to being Authorized Economic Operator and Good Distribution Practices certified, the Mach 2 United Kingdom office is one of just 20 forwarders with Wholesale Distribution Authorization (WDA) granted from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA). Likewise, the Netherlands location is one of only 15 forwarders to earn API storage registration; it has also obtained Japanese Foreign Manufacturer Accreditation, and the facility will soon hold its own Dutch WDA and Manufacturers Import Authorization (MIA) license.

Terms of AIT’s acquisition of Mach II Shipping Ltd have not been disclosed.

About AIT Worldwide Logistics

AIT Worldwide Logistics is a global freight forwarder that helps companies grow by expanding access to markets all over the world where they can sell and/or procure their raw materials, components and finished goods. For more than 40 years, the Chicago-based supply chain solutions leader has relied on a consultative approach to build a global network and trusted partnerships in nearly every industry, including aerospace, automotive, consumer retail, food, government, healthcare, high-tech, industrial and life sciences. Backed by scalable, user-friendly technology, AIT’s flexible business model customizes door-to-door deliveries via sea, air, ground and rail — on time and on budget. With expert teammates staffing more than 130 worldwide locations in Asia, Europe and North America, AIT’s full-service options also include customs clearance, warehouse management and white glove services. Learn more at www.aitworldwide.com.

Our Mission

At AIT, we vigorously seek opportunities to earn our customers’ trust by delivering exceptional worldwide logistics solutions while passionately valuing our co-workers, partners and communities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Matt Sanders
Public Relations Manager
+1 (630) 766-8300
msanders@aitworldwide.com

800-669-4AIT (4248)
www.aitworldwide.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press Release

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn

Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press Release

Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of

500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press Release

500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa

Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press Release

Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la

Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press Release

Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye